Literature DB >> 17468387

Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene.

Mary Jeanne Kreek1, K Steven LaForge.   

Abstract

Discovery and characterization of the functional A118G mu-(mu)-opioid receptor variant led to hypotheses, now in part proven, about its role in alterations of endogenous human physiology and in responses to opioid antagonist administration. Differences in cellular expression levels, ligand binding, and signal transduction for variant receptors have been documented in vitro. Human genetic studies also indicate that individuals carrying one or two copies of the 118G allele may have increased risk for opiate and alcohol addictions and that this polymorphism may also explain some of the variability in success of opioid antagonist treatment for alcoholism. Future research will further define the role of the A118G variant in addictive diseases and their treatment, in pain perception and opioid analgesia, and for a myriad of other responses mediated by the mu-opioid receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468387     DOI: 10.1124/mi.7.2.7

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  28 in total

1.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

Review 2.  Role of a functional human gene polymorphism in stress responsivity and addictions.

Authors:  M J Kreek
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

Review 3.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

4.  Frequency of maternal licking and grooming correlates negatively with vulnerability to cocaine and alcohol use in rats.

Authors:  D D Francis; M J Kuhar
Journal:  Pharmacol Biochem Behav       Date:  2008-04-26       Impact factor: 3.533

Review 5.  Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment.

Authors:  Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2011-08       Impact factor: 5.691

Review 6.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

7.  Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors.

Authors:  Katharine M Seip-Cammack; Brian Reed; Yong Zhang; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2012-07-25       Impact factor: 4.530

8.  Overview and historical perspective of four papers presented on research related to the endogenous opioid system.

Authors:  Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2010-04-18       Impact factor: 4.492

Review 9.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

10.  High-throughput behavioral phenotyping in the expanded panel of BXD recombinant inbred strains.

Authors:  V M Philip; S Duvvuru; B Gomero; T A Ansah; C D Blaha; M N Cook; K M Hamre; W R Lariviere; D B Matthews; G Mittleman; D Goldowitz; E J Chesler
Journal:  Genes Brain Behav       Date:  2009-09-22       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.